• At a June 2, 2026 annual meeting, shareholders adopted Xenon’s 2026 Equity Incentive Plan, replacing the 2014 equity plan.
• Shareholders backed an annual advisory vote on executive pay.
• PricewaterhouseCoopers LLP was ratified as independent auditor for the coming year.
• Shareholders also authorized the audit committee to set the auditor’s remuneration for the coming year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-255396), on June 03, 2026, and is solely responsible for the information contained therein.